|Podcasts|November 17, 2011
Parexel's Ethnobridging Expert Discusses Its Importance as a Development Strategy
Advertisement
Parexel’s Ethnobridging Expert Discusses Its Importance as a Development Strategy
Stan Jhee, PharmD, Senior Director of Research, Early Phase at Parexel, defines the importance of ethnobridging in clinical trials, and how it works as a drug development strategy for pharmaceutical companies.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Articles
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE SummitFebruary 7th 2025
The MDR: Navigating Europe’s New Standard for Medical Device SafetyOctober 25th 2022
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
IQVIA and Veeva Join Forces to Improve Efficiency and Patient Outcomes
2
Everything to Know About FDA’s Push Towards Radical Transparency in 2025
3
Enhancing Clinical Trial Data Accuracy Through the IQVIA and Veeva Partnership
4
Why Clinical Trials Are at a Crossroads and How Site Networks Are the Key to Success
5
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
